The 9 most recent market catalysts affecting $NXTC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bearish
Impact 75
NextCure Announces Workforce Reductions
NextCure has announced workforce reductions, a significant operational change driven by preparations for an upcoming approval decision and a potential merger. This move is a strate…
Nov 11, 2026
Corporate Catalyst
Neutral
Impact 95
NextCure Provides Update on Proposed Merger with Avere Therapeutics
NextCure provided a crucial update on its proposed merger with Avere Therapeutics, confirming the transaction is moving forward with an impressive $820 million in committed financi…
Nov 11, 2026
Corporate Catalyst
Neutral
Impact 85
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
NextCure announced its Q3 2026 financial results, showing a net loss of $6.8 million, an improvement from $8.6 million in Q3 2025. The primary focus of the filing, however, is the …
Oct 31, 2026
Corporate Catalyst
Bearish
Impact 75
NextCure to Terminate Chief Medical Officer Udayan Guha
NextCure is terminating its Chief Medical Officer, Dr. Udayan Guha, effective October 31, 2026. This decision is directly linked to the company's pending merger with Avere Therapeu…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate
NextCure announced its Q2 earnings, reporting a loss of $(2.80) per share, which missed analyst estimates by a substantial 45.08%. This is a critical event for the company as earni…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 95
Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy
NextCure (NXTC) is undergoing a reverse merger with Avere Therapeutics, effectively becoming Avere and trading under a new ticker (AVRX). This is a major strategic pivot for NextCu…
Jul 14, 2026
Market Technicals
Bullish
Impact 60
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
This Benzinga article highlights extreme pre-market volatility in a selection of healthcare stocks. NextCure and Shuttle Pharmaceuticals saw massive gains, while Matinas BioPharma …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 95
NextCure shares are trading higher after the company announced a merger with Avere Therapeutics.
This merger announcement is a major corporate catalyst for NextCure, driving its stock price significantly higher. Mergers often unlock value through synergies, expanded market rea…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 95
NextCure To Merge With Avere Therapuetics In All-Stock Deal; NXTC Holders To Receive A Contingent Value Right For 90% Of Net Proceeds From Any Future License, Divestiture Or Monetization Of Its Pipeline Assets And Programs For Two Years; NXTC Also Announces $320M Private Placement
NextCure (NXTC) is undergoing a reverse merger with Avere Therapeutics, a privately-held biotech, in an all-stock transaction. This effectively transforms NextCure into Avere Thera…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.